1. Switzerland Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Roche Holding AG

Roche Holding AG

ROG.SW
Roche Holding AGCH flagSwiss Exchange
322.30
CHF
+1.60
- -
256.55BMarket Cap
Roche Holding AG
ROG.SW
(Swiss Exchange)

Recent

price

322.30

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
55.52
50.1
53.65
55.17
55.9
56.57
59.36
62.48
66.56
71.81
68.21
73.88
82.27
75.65
78.29
79.59
Revenue per Share
10.14
11
11.12
13.17
10.99
10.41
11.24
10.12
12.3
15.77
16.72
16.39
15.53
14.39
10.39
16.18
Basic EPS, GAAP
13.25
12.66
14.86
15.23
14.84
13.09
11.57
16.19
17.63
20.43
13.89
19.33
16.56
14.33
18.93
16.42
Free Cash Flow per Basic Share
6.16
6.76
6.94
7.5
7.91
8.17
8.26
8.37
8.49
8.7
9.01
9.14
9.31
9.5
9.6
9.71
Dividend per Share
17.2
20.55
23.82
30.43
30.99
33.78
36.68
39.19
41.09
47.53
53.49
40.38
48.8
53.13
55.14
61.49
Book Value per Share
-1.4
1.81
5.96
11.97
-1.38
-1.93
3.61
12.38
14.14
17.31
21.65
6.38
14.39
11.32
13.78
13.9
Tangible Book Value per Share
855
849
848
848
849
851
852
853
854
856
855
850
800
799
797
796
Basic Weighted Avg Shares
47,473
42,531
45,499
46,780
47,462
48,145
50,576
53,299
56,846
61,466
58,323
62,801
65,814
60,441
62,395
63,356
Sales/Revenue/Turnover
28.37
31.6
31.04
35.01
29.69
28.71
27.82
24.4
25.98
28.55
31.79
28.91
26.55
25.47
21.5
29.16
Operating Margin (%)
2,552
2,368
2,421
2,381
2,623
3,640
3,941
3,887
3,586
4,292
4,558
4,443
3,844
3,464
3,423
3,386
Depreciation Expense
8,666
9,343
9,427
11,164
9,332
8,863
9,576
8,633
10,500
13,497
14,295
13,930
12,421
11,498
8,277
12,880
Net Income, GAAP
20.69
19.7
20.55
22.51
23.81
24.45
25.17
27.95
23.2
15.08
16.13
14.16
17.13
12.22
22.1
18.7
Effective Tax Rate (%)
18.25
21.97
20.72
23.86
19.66
18.41
18.93
16.2
18.47
21.96
24.51
22.18
18.87
19.02
13.27
20.33
Profit Margin (%)
12,634
12,022
11,162
13,404
8,006
4,414
6,070
9,412
9,211
7,135
7,541
-2,789
6,577
8,622
13,013
10,728
Working Capital
27,857
23,459
17,860
16,423
19,347
17,100
16,992
15,839
16,077
13,547
11,096
17,101
22,282
26,092
32,097
28,674
LT Debt
11,662
14,506
16,750
21,241
21,558
23,300
26,402
29,007
30,366
35,867
39,773
28,345
32,015
33,263
36,161
37,880
Total Equity
21.75
24.73
25.81
29.84
23.5
21.12
20.95
18.26
21.79
27.59
27.28
25.4
23.07
21.1
14.73
20.08
Return on Invested Capital (%)
20.17
23.02
22.44
25.66
19.97
17.56
18.36
16.19
19.23
23.38
22.57
19.64
16.93
15.69
10.45
15.28
Return on Capital (%)
64.9
58.11
50.08
48.53
35.81
32.19
31.92
26.7
30.65
35.62
33.08
34.8
33.86
28.22
19.16
27.73
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.85%
0.32%
4.75%
Free Cash Flow
4.55%
4.76%
-13.34%
Net Income, GAAP
6.11%
1.36%
55.61%
Sales/Revenue/Turnover
2.92%
1.82%
1.54%
Total Cash Common Dividend
1.08%
0.1%
1.06%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
60,441
2024
- -
- -
- -
- -
62,395
2025
- -
- -
- -
- -
63,356

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
14.39
2024
- -
- -
- -
- -
10.39
2025
- -
- -
- -
- -
16.18

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
9.5
2024
- -
- -
- -
- -
9.6
2025
- -
- -
- -
- -
9.71
Similar Companies
Sanofi India Limited (SANOFI.BO)
Bayer Aktiengesellschaft (BAYN.DE)
GSK plc (GS7.DE)
Nissui Pharmaceutical Co., Ltd. (4550.T)
Clarus Therapeutics Holdings, Inc. (CRXTQ)
Biogen Inc. (BIIB)
Business
Roche Holding AG, founded in 1896 and headquartered in Basel, Switzerland, operates as a leading multinational healthcare company focused on pharmaceuticals and diagnostics; it develops and markets prescription medicines for oncology, immunology, infectious diseases, neuroscience, ophthalmology, haemophilia, inflammatory and respiratory diseases, and cardiovascular, renal and metabolic disorders; and offers a broad portfolio of in vitro diagnostic tests and instruments for diseases including cancer, diabetes, cardiovascular conditions, infectious diseases such as COVID-19, hepatitis and human papillomavirus, women's health, and point-of-care solutions like the recently FDA-cleared Liat Bordetella test for whooping cough; its diagnostics division encompasses professional diagnostics, molecular diagnostics, diabetes care, tissue diagnostics via Ventana, and digital health solutions for laboratories, healthcare providers and patients. The company conducts research and development, manufacturing and sales in more than 100 countries worldwide, serving physicians, hospitals, clinics, research institutions, pharmaceutical industries and consumers. Recent developments include a USD 50 billion investment over five years in US pharmaceuticals and diagnostics facilities for gene therapy, AI R&D and manufacturing expansions creating 12,000 jobs; entry into a definitive merger agreement in September 2025 to acquire 89bio and its phase 3 FGF21 analog pegozafermin for moderate to severe MASH; acquisitions of Carmot Therapeutics for USD 2.7 billion in 2024, Televant Holdings for USD 7.1 billion in 2023 and Good Therapeutics’ PD-1 programme; a USD 550 million expansion of its Indianapolis diagnostics manufacturing site by 2030 for continuous glucose monitoring; and multiple partnerships such as with Innovent Biologics for antibody-drug conjugates, Poseida Therapeutics for CAR-T therapy, and deals in China including with Regor Pharmaceuticals for CDK inhibitors.